PADL1NK-005: A Randomized, Phase 3, Open-Label Study to Evaluate PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
PADL1NK-005: A Randomized, Phase 3, Open-Label Study to Evaluate PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
The purpose of this study is to understand if PF-08046054 alone works well compared to standard-of-care docetaxel alone in participants with non-small cell lung cancer (NSCLC) with PD-L1 expression greater than or equal to 1% and had cancer progression during or after treatment with PD-L1 or PD-1 inhibitors, platinum-based chemotherapy, and targeted treatment regimen(s) for participants with known actionable genomic alterations (AGAs). Participants in this study must have cancer that has spread through their body or can't be removed with surgery or treated with definitive radiation.
Participants will randomly (like a flip of the coin) be assigned to either the PF-08046054 treatment group or the docetaxel treatment group. Participants in the PF-08046054 treatment group will receive an IV infusion (injected directly into the veins) twice during each 21-day cycle. Participants in the docetaxel treatment group will receive an IV infusion once during each 21-day cycle. Study participation may be up to 5 years if the participant's NSCLC is responding to treatment. The study team will see how each participant is doing with the study treatment during regular visits at the clinic.
Inclusion Criteria
Histologically or cytologically confirmed diagnosis of NSCLC with locally advanced, unresectable Stage IIIB or IIIC not eligible for definitive chemoradiotherapy or metastatic (Stage IV: M1a, M1b, or M1c) disease per the American Joint Committee on Cancer (AJCC) Staging Manual, Version 8.0, and the Union for International Cancer Control (UICC) Staging System. Note: Participants with a neuroendocrine component or histology are not eligible.
PD-L1 expression on ≥1% of tumor cells based on local immunohistochemistry (IHC) testing with an assay utilizing the anti-PD-L1 monoclonal antibody clones 22C3 or SP263.
Participants who have NSCLC with known AGAs are permitted.
Able to provide any of the following tumor tissues for biomarker analysis:
Participants must have received the following therapies and progressed during or relapsed after receiving their most recent prior therapy, or have been intolerant to their most recent therapy:
Participants with no known AGAs must fulfill 1 of the following conditions:
Participants with known AGAs (eg, EGFR mutations, ALK translocations, or other relevant actionable mutations) must fulfill the following conditions:
Exclusion Criteria
History of another malignancy within 3 years before the first dose of PF-08046054, or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death (eg, 5-year overall survival [OS] ≥90%), such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer.
Any central nervous system (CNS) lesions, unless definitively treated with CNS-directed local therapy (surgery and/or radiotherapy). Participants with definitively treated brain metastases are eligible if they meet the following criteria:
Participants with a history of leptomeningeal metastasis are excluded.
Prior treatment with an anti-PD-L1 agent (where indicated per protocol) within 5 half-lives.
Previous receipt of an MMAE-containing agent or prior docetaxel.
There are additional inclusion and exclusion criteria. The study center will determine if criteria for participations are met.
ClinicalTrials.gov_Inquiries@pfizer.com1-800-718-1021
Berkeley, California 94704, United States
La Jolla, California 92037, United States
Roseville, California 95661, United States
Sacramento, California 95816, United States
San Diego, California 92103, United States
Peru, Illinois 61354, United States
Louisville, Kentucky 40241, United States
Coon Rapids, Minnesota 55433, United States
Minneapolis, Minnesota 55407, United States
Saint Paul, Minnesota 55102, United States
Billings, Montana 59102, United States
Bozeman, Montana 59715, United States
Bozeman, Montana 59715, United States
The Bronx, New York 10461, United States
Avon, Ohio 44011, United States
Mentor, Ohio 44060, United States
Broomall, Pennsylvania 19008, United States
Chattanooga, Tennessee 37403, United States
Chattanooga, Tennessee 37404, United States
Chattanooga, Tennessee 37404, United States
Chattanooga, Tennessee 37404, United States
Mount Juliet, Tennessee 37122, United States
Murfreesboro, Tennessee 37129, United States
Nashville, Tennessee 37203, United States
Nashville, Tennessee 37203, United States
Nashville, Tennessee 37205, United States
Conroe, Texas 77384, United States
Houston, Texas 77030, United States
Houston, Texas 77030, United States
Houston, Texas 77054, United States
Houston, Texas 77079, United States
League City, Texas 77573, United States
Lubbock, Texas 79410, United States
Sugar Land, Texas 77478, United States
Blacksburg, Virginia 24060, United States
Low Moor, Virginia 24457, United States
Roanoke, Virginia 24014, United States
Salem, Virginia 24153, United States
Wytheville, Virginia 24382, United States
Olympia, Washington 98502, United States
Olympia, Washington 98506, United States
Ciudad Autónoma de Buenos Aires, Buenos Aires C1426ABP, Argentina
Passo Fundo, Rio Grande do Sul 99010-260, Brazil
São Paulo, 05652-900, Brazil
Haskovo, 6300, Bulgaria
Sofia, 1756, Bulgaria
Laval, Quebec H7M 3L9, Canada
Québec, G1J 1Z4, Canada
Beijing, Beijing Municipality 100050, China
Wuhan, Hubei 430030, China
Ostrava, Ostrava Město 703 00, Czechia
Brno, 625 00, Czechia
Helsinki, Uusimaa 00029, Finland
Rennes, Ille-et-vilaine 35033, France
Saint-Herblain, Loire-atlantique 44800, France
Koblenz, Rhineland-Palatinate 56068, Germany
Athens, 115 26, Greece
New Delhi, National Capital Territory of Delhi 110085, India
Kerala, 686630, India
Ramat Gan, Central District 5265601, Israel
Verona, Veneto 37126, Italy
Kure, Hiroshima 737-0023, Japan
Beppu-shi, Oita Prefecture 874-0011, Japan
Nagaizumi-cho, Shizuoka 411-8777, Japan
Bunkyo-ku, Tokyo 113-8603, Japan
Kiyose, Tokyo 204-8585, Japan
Puebla City, 72530, Mexico
Krakow, Lesser Poland Voivodeship 30-348, Poland
Poznan, 60-569, Poland
Tomaszów Mazowiecki, 97-200, Poland
Cheongju-si, Chungcheongbuk-do [chungbuk] 28644, South Korea
Suwon, Kyǒnggi-do 16247, South Korea
Haeundae-gu, Pusan-kwangyǒkshi 48108, South Korea
Dongjak-gu, Seoul-teukbyeolsi [seoul] 07061, South Korea
Seoul, Seoul-teukbyeolsi [seoul] 03722, South Korea
Seoul, Seoul-teukbyeolsi [seoul] 06591, South Korea
A Coruña, A Coruña [LA Coruña] 15006, Spain
Changhua County, Changhua 50006, Taiwan